Navamedic ASA
OSE:NAVA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (1), the stock would be worth kr23.74 (23% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.8 | kr19.3 |
0%
|
| 3-Year Average | 1 | kr23.74 |
+23%
|
| 5-Year Average | 1.3 | kr31.58 |
+64%
|
| Industry Average | 3.9 | kr91.13 |
+372%
|
| Country Average | 2.1 | kr49.08 |
+154%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
kr472.4m
|
/ |
Jan 2026
kr565.4m
|
= |
|
|
kr472.4m
|
/ |
Dec 2026
kr675.2m
|
= |
|
|
kr472.4m
|
/ |
Dec 2027
kr763m
|
= |
|
|
kr472.4m
|
/ |
Dec 2028
kr828.2m
|
= |
|
|
kr472.4m
|
/ |
Dec 2029
kr866.4m
|
= |
|
|
kr472.4m
|
/ |
Dec 2030
kr892.5m
|
= |
|
|
kr472.4m
|
/ |
Dec 2031
kr918.5m
|
= |
|
|
kr472.4m
|
/ |
Dec 2032
kr946.6m
|
= |
|
|
kr472.4m
|
/ |
Dec 2033
kr974.6m
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| NO |
N
|
Navamedic ASA
OSE:NAVA
|
462.8m NOK | 0.8 | -19.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
804.2B USD | 12.3 | 39 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.4B USD | 5.7 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.2 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.4B GBP | 4.8 | 27.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
220.1B CHF | 4.8 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
274.6B USD | 4.2 | 15 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 3.7 | 11.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.3B USD | 2.4 | 19.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.9B USD | 2.4 | 16.4 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 1.1 |
| Median | 2.1 |
| 70th Percentile | 4 |
| Max | 77 165 |
Other Multiples
Navamedic ASA
Glance View
Navamedic ASA engages in the delivery and marketing of pharmaceutical products to patients, hospitals, and pharmacies. The company is headquartered in Oslo, Oslo. The company went IPO on 2006-03-31. The firm in-licenses, acquires and markets pharmaceuticals and other healthcare products in northern Europe. The product portfolio includes original and generic pharmaceuticals, as well as food supplements, medical devices and other healthcare products. Navamedic ASA has three subsidiaries: Observe Medical, a Swedish medical technology company; Vitaflo Scandinavia AB, which focuses on in-licensing and buying pharmaceuticals and other healthcare products within a few selected knowledge areas; and Navamedic ehf, which builds its business around the sales and marketing of generic pharmaceuticals targeted towards the Nordic and BeNeLux markets. The Navamedic business unit is built upon the cooperation with the South African pharmaceutical company Aspen Healthcare. The Company’s largest shareholder is Nobelsystem Scandinavia.
